- within Food, Drugs, Healthcare and Life Sciences topic(s)
- within Food, Drugs, Healthcare and Life Sciences topic(s)
- within Food, Drugs, Healthcare, Life Sciences, Intellectual Property and Insurance topic(s)
Journal
At the beginning of September 2025, the Swiss Federal Council published the dispatch for the partial revision of the Therapeutic Products Act (TPA). The revision aims to promote digitalization in the prescription, dispensing, and use of therapeutic products, enhance medication safety in pediatrics, regulate access to novel therapies, and align Swiss law with EU law for veterinary medicinal products. The draft is now before Parliament, with deliberation timing still uncertain. It currently lacks transitional provisions, leaving the timeline for technical adjustments unclear. Nonetheless, healthcare institutions should begin planning and budgeting for the necessary digital infrastructure and ensure compliance with data protection. The impact on health insurance law and tariffs will hinge on future negotiations.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
